Abstract

Simple SummaryThe concept of utilizing mesenchymal stem cells for the treatment of central nervous system disorders has progressed from preclinical studies to clinical trials. While promising, the effectiveness of cell therapy is hampered by the route used to deliver cells into the brain. In this context, intranasal cell administration has boomed over the past few years as an effective cell delivery method. However, comprehensive safety studies are required before translation to the clinic. Our study shed light on how intranasally administrated mesenchymal stem cells may be used to safely treat neurological disorders.Mesenchymal stem cell (MSC)-based therapy is a promising therapeutic approach in the management of several pathologies, including central nervous system diseases. Previously, we demonstrated the therapeutic potential of human adipose-derived MSCs for neurological sequelae of oncological radiotherapy using the intranasal route as a non-invasive delivery method. However, a comprehensive investigation of the safety of intranasal MSC treatment should be performed before clinical applications. Here, we cultured human MSCs in compliance with quality control standards and administrated repeated doses of cells into the nostrils of juvenile immunodeficient mice, mimicking the design of a subsequent clinical trial. Short- and long-term effects of cell administration were evaluated by in vivo and ex vivo studies. No serious adverse events were reported on mouse welfare, behavioral performances, and blood plasma analysis. Magnetic resonance study and histological analysis did not reveal tumor formation or other abnormalities in the examined organs of mice receiving MSCs. Biodistribution study reveals a progressive disappearance of transplanted cells that was further supported by an absent expression of human GAPDH gene in the major organs of transplanted mice. Our data indicate that the intranasal application of MSCs is a safe, simple and non-invasive strategy and encourage its use in future clinical trials.

Highlights

  • Cell therapy is an important component of regenerative medicine that has shown promising results over the past few years

  • Results of the quality control (QC) indicated that all Mesenchymal stem cell (MSC) met the criteria established for the Good Manufacturing Practice (GMP) requirements at the time of cell transplantation

  • Results indicated that human was undetected by in the brain, the brain is of particular interest in this study, we examined this tissue separately to avoid a lung, kidney, liver, spleen, stomach, heart, skeletal muscle, and testicle of MSC and U87 masking effect due to the high fluorescence signal in the stomach

Read more

Summary

Introduction

Cell therapy is an important component of regenerative medicine that has shown promising results over the past few years. Mesenchymal stem cells (MSCs) are one of the most extensively explored cell type in cell-based treatments due to numerous advantages [1,2,3,4,5,6,7,8]. MSC-based therapy has emerged as an attractive alternative in the treatment of neurological disorders, such as stroke, brain cancer, Friedreich’s ataxia, traumatic brain injury, and white matter damage, among others [11,12,13,14,15,16,17]. The route of cell delivery to the brain may represent a major limitation for the effectiveness of central nervous system (CNS) therapies. Systemic administration is a widely used method in preclinical and clinical research, but this route has a reduced therapeutic effectiveness because the blood–

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call